Drug
Tepotinib
Tepotinib: highest development phase Phase 1/2, developed by Merck. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tepotinib NCT02115373 | Phase 1/2 | Carcinoma, Hepatocellular |
| Tepotinib (HydroChloride hydrate) NCT05203822 | Phase 1 | Healthy |
Latest
No recent events.
Follow Tepotinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.